Company news

Lipocine Inc. news in 2022

Lipocine Inc.'s news releases, calls and decks from 2022, newest first.

View company

Lipocine Completes Enrollment of LPCN 1148 Phase 2 Study for Decompensated Cirrhosis

December 18, 2022

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

November 8, 2022

Lipocine Announces Senior Leadership Appointments to Advance its CNS-Focused Pipeline

November 2, 2022

Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders

September 25, 2022

Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD)

September 14, 2022

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022

August 7, 2022

FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment

July 10, 2022

Lipocine granted US patents directed to CNS and liver programs

June 13, 2022

Lipocine announces presentation at 2022 epilepsy foundation pipeline conference

June 5, 2022

Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results

May 11, 2022

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022

May 8, 2022

Lipocine announces board of director appointments

April 10, 2022

Lipocine announces its partner received FDA approval of TLANDO™

March 28, 2022

Lipocine Announces Financial Results for the Year Ended December 31, 2021

March 8, 2022

Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH

February 28, 2022

Lipocine announces its partner received FDA acceptance of NDA resubmission for TLANDO®

February 2, 2022

Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®

January 26, 2022

Decks in 2022